

## AGENDA GCG Meeting 2017

29 – 30 September 2017

Venue: Instituto Português de Oncologia do Porto (IPO)  
Rua António Bernardino de Almeida 4200-072, Porto, Portugal  
Room: "Blue Auditorium" – Medicin building, 1st floor

### Friday 29th September 2017

Time slot	Topic / Title of presentation	Moderator
8.30 – 10.00	Young investigators meeting (names to be provided)	Dr. N. Ottevanger (Nijmegen, The Netherlands)/ Dr. A. Casado (Madrid, Spain)
10.00 – 10.15	<i>Coffee break</i>	
10.15 – 11.15	<p><b>Ovarian Tumor Site Committee (including new ideas)</b></p> <ul style="list-style-type: none"> <li>• <b>EORTC 1508:</b> A phase II study of the anti-PDL1 antibody atezolizumab, bevacizumab and acetylsalicylic acid to investigate safety and efficacy of this combination in recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal adenocarcinoma (EORTC GCG PI: A. Wolfer)</li> <li>• <b>EORTC 1212.</b> DGCG/NCRI (GCIG/ENGOT proposal). Vargatef in recurrent clear cell ovarian and endometrial cancer (EORTC GCG PI: A. Westermann).</li> <li>• <b>EORTC 55092:</b> Phase Ib/II of pazopanib and weekly paclitaxel / carboplatin in recurrent platinum resistant ovarian carcinoma (EORTC GCG PI: I. Vergote).</li> <li>• <b>New proposals</b> <b>ICON9:</b> An international phase III randomised study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy (EORTC GCG PI: N. Ottevanger).</li> </ul>	Dr. I. Boere (Rotterdam, The Netherlands)
11.15 – 12.00	<p><b>Endometrial Tumor Site Committee (including new ideas)</b></p> <ul style="list-style-type: none"> <li>• <b>EORTC 62113-55115.</b> (EORTC/CRUK/NCI) A randomized phase II study of maintenance therapy with cabozantinib in High Grade Uterine Sarcoma. (EORTC STBSG PI: I. Ray Coquard. EORTC GCG PI: N. Reed.)</li> <li>• <b>ENGOT-EN2-DGCG / EORTC 55102:</b> A phase III trial of chemotherapy or no further treatment for patients with stage I-II medium or high risk endometrial cancer. (DGCG PI: M. Raza Mirza; EORTC PI: F. Amant).</li> <li>• New proposals</li> </ul>	Dr. A Sadozye (Glasgow, UK)
12.00 – 12.30	<p><b>Cervix Tumor Site Committee (including new ideas)</b></p> <ul style="list-style-type: none"> <li>• <b>EORTC 55994:</b> Phase III study of neoadjuvant chemotherapy followed by surgery vs. concomitant radiotherapy and chemotherapy in FIGO Ib2, IIa &gt; 4 cm or IIb cervical cancer (EORTC GCG PI: G. Kenter)</li> </ul>	Dr. Eleonora van Dorst (Utrecht, The Netherlands)

## AGENDA GCG Meeting 2017

29 – 30 September 2017

Venue: Instituto Português de Oncologia do Porto (IPO)  
Rua António Bernardino de Almeida 4200-072, Porto, Portugal  
Room: "Blue Auditorium" – Medicin building, 1st floor

12.30 – 13.30	<i>Lunch</i>	
<b>13.30 – 18.00</b>	<b>Scientific program</b> Chair: Dr. N. Ottevanger (Nijmegen, The Netherlands)	
13.30 – 13.45	Welcome and introduction	
13.45 – 15.15	<b>Session I.</b> <ul style="list-style-type: none"> <li>• Organoids for research on platinum resistant ovarian cancer. (20 minutes + 10 minutes discussion)</li> <li>• Tumor microenvironment in cervical cancer and tumor draining lymph nodes: identifying immunotherapy targets (20 minutes + 10 minutes discussion)</li> <li>• Application of circulating tumor DNA in prospective clinical oncology trials – standardization of preanalytical conditions (20 minutes + 10 minutes discussion)</li> </ul>	<p>Dr. Chris de Witte (Utrecht, The Netherlands)</p> <p>Dr. Katja Jordanova (Amsterdam, The Netherlands)</p> <p>Dr. Lisanne van Dessel (Rotterdam, The Netherlands)</p>
15.15 – 16.15	<i>Coffee break</i>	
16.15 – 17.15	<b>Session 2.</b> <ul style="list-style-type: none"> <li>• Tumor heterogeneity and response to targeted drugs: a novel cost-effective tumor profiling method to aid diagnosis and guide therapy choices ((20 minutes + 10 minutes discussion)</li> <li>• Opportunities for cooperation between the EORTC Gynecological Cancer group and the Pathobiology group. (20 minutes + 10 minutes discussion)</li> </ul>	<p>Dr. William Leenders (Nijmegen, The Netherlands)</p> <p>Dr. Riccardo Spizzo (Aviano, Italy)</p>
20.00 -	<i>Dinner</i> <i>Venue: Restaurant Vinum at Grahams – Rua do Agro 141 4400-281, Vila Nova de Gaia</i>	

## AGENDA Autumn Meeting 2017

29 – 30 September 2017

Venue: Instituto Português de Oncologia do Porto (IPO)  
Rua António Bernardino de Almeida 4200-072, Porto, Portugal  
Room: "Blue Auditorium" – Medicin building, 1st floor

### Saturday 30th September 2017

Time slot	Topic / Title of presentation	Moderator
09.00 – 10.30	<b>General Assembly and Business meeting</b> <ul style="list-style-type: none"> <li>• Announcements: <ul style="list-style-type: none"> <li>○ New memberships (Fernanda Herrera)</li> <li>○ Next meetings location and dates</li> </ul> </li> <li>• Reports: <ul style="list-style-type: none"> <li>○ Financial report (A. Casado)</li> </ul> </li> </ul>	Dr. N. Ottevanger (Nijmegen, The Netherlands)
10.30 – 11.00	<b>ROG/GCG working party</b>	Dr. F. Herrera (Lausanne, Switzerland)
11.00 – 11.15	<i>Coffee break</i>	
11.15 – 11.45	<b>Survivorships and quality of life issues</b> <ul style="list-style-type: none"> <li>• <b>EORTC 1514:</b> Follow-up in Gynecological Cancer Survivors: An EORTC QLQ-GCG Survivorship Protocol (EORTC QLQ PI: E. Greimel; EORTC GCG PI: A. Casado)</li> </ul>	Dr. E. Greimel (Graz, Austria) / E. van Dorst (Utrecht, The Netherlands)
11.45 – 12.15	<b>Quality Assurance Subcommittee</b>	Dr. A. Ferrero (Torino, Italy)
12.15 – 13.15	<i>Lunch</i>	
13.15 – 14.45	<b>Translational Research Subcommittee</b>	Dr. K. Jordanova (Amsterdam, Netherlands)
14.45 – 15.00	<b>Closure of the meeting</b>	